GoldenGolden
Advanced Search
Vertex Pharmaceuticals

Vertex Pharmaceuticals

Vertex Pharmaceuticals discovers, develops and commercializes pharmaceutical products for treatment of cystic fibrosis, cancer, inflammatory bowel, autoimmune disease and neurological disorders.

Vertex Pharmaceuticals discovers, develops and commercializes pharmaceutical products for treatment of cystic fibrosis, cancer, inflammatory bowel, autoimmune disease and neurological disorders. Vertex’s product Trikafta was approved by the USFDA in 2019 for treatment of cystic fibrosis. Other approved cystic fibrosis medicines from Vertex include Symdeko, Orkambi and Kalydeco.

Vertex and CRISPR Therapeutics are collaborating with their treatment, CTX001, made from a patient’s own stem cells harvested and edited using CRISPR technology to increase fetal hemoglobin levels to treat transfusion-dependent beta thalassemia and sickle cell disease.

Timeline

People

Name
Role
LinkedIn

Adriana Kwiatkowski

Employee

Adrija Ashrita

Employee

Alison Welch

Employee

Allan Powe

Employee

Andreas Kateifides

Employee

Andrei Jerkovich

Employee

Andrew Berkowitz

Employee

Andrew Cosgrove

Employee

Ankita Deshpande

Employee

Arash Shirazi

Employee

Bob Stack

Employee

Bradford Kellogg

Employee

Brett Busch, Ph.D.

Employee

Carlo Bocconcelli

Employee

Chandra Burra

Employee

Chelsea Lombardi

Employee

Chelsey Jensen

Employee

Chong Lee

Employee

Chris Hughes

Employee

Christina Han

Employee

Corey Gray

Employee

Courtney Bradford

Employee

David Howe

Employee

Dr Janet Fernihough MBA

Employee

Edward Ramos

Employee

Page 1 of 4

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
DelveInsight Business Research, LLP
June 24, 2021
www.prnewswire.com:443
/PRNewswire/ -- DelveInsight's Chronic Obstructive Pulmonary Disease (COPD) Market report puts forward a detailed perspective on epidemiology, current...
Alex Keown
June 11, 2021
BioSpace
Shares of Vertex fell more than 13% in premarket trading after it announced that it will not advance a novel small molecule corrector of the Z-AAT protein into a Phase III study.
Amirah Al Idrus
April 22, 2021
FierceBiotech
Vertex Pharmaceuticals is inking another gene-editing deal, days after retooling a partnership with CRISPR Therapeutics to the tune of $900 million. This time, the company is teaming up with Obsidian Therapeutics to discover new gene-editing treatments that can be controlled with small molecules.
Mark Terry
April 20, 2021
BioSpace
Under the terms of the expanded deal, Vertex will be responsible for 60% of the costs of developing, manufacturing and commercializing CTX001 with support from CRISPR Therapeutics, and will receive 60% of profits from global sales.
BioSpace
April 13, 2021
BioSpace
Elliot Ehrich MD brings 25+ years R&D and clinical development leadership experience to the company; Graeme Smith PhD DABT brings 15+ years of nonclinical drug development leadership experience to the company.
BioSpace
November 17, 2020
BioSpace
Brings 25 years of experience in the pharmaceutical and biotech industries and a deep understanding of global regulatory strategy and commercial regulatory affairs
Alex Keown
May 8, 2020
BioSpace
Pharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
August 28, 2019
news.yahoo.com
Patent cliffs and pipeline risks are among the reasons these biologic drug specialists are attractively priced today.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.